NCT03383822 (NI EGP highBMI) is a Phase 1, PHASE2 clinical trial of Intranasal insulin in Insulin Resistance, sponsored by University Health Network, Toronto.

Who is sponsoring NCT03383822?

NCT03383822 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT03383822?

Interventions in NCT03383822: Intranasal insulin, Intranasal placebo.

What condition does NCT03383822 study?

NCT03383822 studies Insulin Resistance.

Is NCT03383822 still recruiting?

NCT03383822 is currently completed. Last updated 26 December 2017.

Last reviewed 2017-12-26 · How we verify

NCT03383822: NI EGP highBMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance

Completed Phase 1, PHASE2 Last updated 26 December 2017

What this trial tests

Phase 1, PHASE2 trial testing Intranasal insulin in Insulin Resistance in 7 participants. Completed in 1 December 2017.

Timeline

8 September 2015

Primary endpoint
31 July 2017

1 December 2017

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	7
Start date	8 September 2015
Primary completion	31 July 2017
Estimated completion	1 December 2017
Sites	1 location across Canada

Drugs / interventions tested

Intranasal insulin — full drug profile →
Intranasal placebo — full drug profile →

Conditions studied

Insulin Resistance — all drugs for Insulin Resistance →

Sponsor

University Health Network, Toronto

Who can join

Adults 18 to 60, any sex, with Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is well known that the hormone insulin lowers blood glucose in part by acting directly on the liver and reducing hepatic glucose production. Animal studies have shown that the hormone insulin can act on the brain to indirectly lower glucose production by the liver. It has previously been shown that a nasal spray can deliver insulin directly to the brain without affecting circulating insulin concentration in humans. Intranasal spray of insulin suppressed hepatic glucose production in lean subjects. It is unknown whether this effects is blunted in subjects with insulin resistance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Intranasal insulin

Trials testing the same drug.

NCT04044534 — Intranasal Insulin for Posttraumatic Stress Disorder · Phase 2 · recruiting
NCT06072963 — COMMETS- Combination MCI Metabolic Syndrome · Phase 2 · recruiting
NCT06144255 — Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI) · Phase 1 · completed
NCT05748990 — Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia · NA · recruiting
NCT05613491 — Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients · NA · unknown

Other recruiting trials for Insulin Resistance

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity · Phase 2 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06768827 — New Mechanisms of Obesity · NA · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03383822 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 26 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03383822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing